KOE:214450
PharmaResearch Co., Ltd. · KOE · Healthcare · KRW · FY for 2025
Figures on this page computed 2026-11-08 13:48 UTC
Last close
n/aKRW
Market data
14.8xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
22.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
30.8%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
28.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.31Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.5%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Follow one won
lens 1 of 9After what it costs to make
75.1%
After running the business
39.6%
After interest and tax
30.8%
After what it must reinvest
28.7%
Kept after the dividend
26.6%
The five stops
5 of 5 read- After what it costs to make402,425,177,00075.1%
- After running the business212,326,594,00039.6%
- After interest and tax165,120,956,00030.8%
- After what it must reinvest153,733,405,00028.7%
- Kept after the dividend142,304,792,00026.6%
Of every unit of sales, 0.27 is still there after the dividend.
Of every unit of sales, 0.27 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales535,722,606,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After what it costs to make402,425,177,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After running the business212,326,594,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After interest and tax165,120,956,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
After what it must reinvest153,733,405,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
Kept after the dividend142,304,792,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW